Sillon Guillaume, Joly Yann, Feldman Sabrina, Avard Denise
Centre de recherche en droit public, Université de Montréal, Montréal, Quebec, Canada.
Med Law. 2008 Dec;27(4):843-57.
Pharmacogenomics, a field of study at the interface of the disciplines of genomics and pharmacology, strives to understand the interaction between genes and the response to therapeutics. Its introduction into clinical research trials and medical practice promises to optimize the effectiveness of medications, reduce the adverse effects experienced by patients, and improve the research and development of new therapeutics. However, while pharmacogenomics promises tremendous health benefits it is still crucial to critically analyze the ethical, social and legal issues surrounding these developments. First, we present the numerous potential benefits ofpharmacogenomics. Then, using a thorough review of relevant jurisprudence, policies and literature, the main ethical, social and legal issues associated with pharmacogenomics will be identified. The likely new responsibilities for health care professionals and pharmaceutical companies as a result of pharmacogenomic development will also be discussed.
药物基因组学是基因组学和药理学交叉的一个研究领域，致力于理解基因与治疗反应之间的相互作用。将其引入临床研究试验和医疗实践有望优化药物疗效、减少患者所经历的不良反应，并改善新疗法的研发。然而，尽管药物基因组学有望带来巨大的健康益处，但批判性地分析围绕这些发展的伦理、社会和法律问题仍然至关重要。首先，我们阐述药物基因组学的众多潜在益处。然后，通过全面回顾相关判例法、政策和文献，确定与药物基因组学相关的主要伦理、社会和法律问题。还将讨论药物基因组学发展可能给医疗保健专业人员和制药公司带来的新责任。
